期刊文献+

红色荧光蛋白标记的小鼠白血病模型的建立

Establishment of DsRed-labled leukemia mouse model
原文传递
导出
摘要 目的 利用红色荧光蛋白(DsRed)标记的小鼠淋巴瘤EL4细胞株,建立荧光标记的小鼠白血病模型,并对模型进行分析和鉴定.方法 将EL4/DsRed细胞以低剂量(5×10^2/只)、中剂量(5×10^3/只)、高剂量(2.5×10^4/只)经尾静脉注入经清髓照射的C57BL/6小鼠体内,同时接种骨髓细胞5×10^6/只,采用流式细胞术(FCM)、反转录聚合酶链反应(RT-PCR)、组织病理等方法鉴定小鼠成模情况.结果 C57BL/6小鼠接种不同剂量EL4/DsRed细胞后白血病发病率达100%,移植后第2周FCM示受鼠肝、脾、骨髓和外周血中有大量EL4/DsRed细胞;各组组织器官病理检查呈现出不同程度的肿瘤细胞浸润.结论 用DsRed标记的EL4细胞以5×10^2/只植入C57BL/6小鼠,即可成功建立荧光标记的小鼠白血病模型,可为白血病发病机制、微小残留病检测等研究提供有价值的动物模型. Objective This study aimed to establish the leukemia mouse model by using EL4/DsRed cell line expressing red fluorescent protein (DsRed) and to evaluate the model. Methods After total body irradiation with X-ray of 7.0 Gy, C57BL/6 mice were inoculated 5×106 bone marrow cells mixed different numbers of EL4/DsRed cells via tail vein. The model was evaluated by flow cytometry (FCM), reverse transcriptase-polymerase chain reaction (RT-PCR), and histopathology. Results The incidence of leukemia was 100 %. The presence of EL4/DsRed cells was found in liver, spleen, bone marrow and peripheral blood of recipients by FCM two weeks after transplantation. Pathological section revealed that all recipients had several organs infiltration apparently. With the increase in the number of inoculated tumor cells, the survival time of recipients was reduced and the infiltration of leukemia cells in organs was more serious. Conclusion Mouse leukemia model was successfully established when C57BL/6 mouse was intravenously transplanted with ≥5×10^2 EIA/DsRed cells. The model could be employed usefully in the future research such as the pathogenesis of leukemia and minimal residual disease (MRD).
出处 《白血病.淋巴瘤》 CAS 2010年第9期548-551,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金(30770915)
关键词 荧光抗体技术 白血病 实验性 Fluorescent antibody technique Leukemia, exprimental
  • 相关文献

参考文献12

  • 1聂小蒙,楼敬伟,王建民.SCID小鼠-人白血病模型在白血病研究中的应用[J].中国实验血液学杂志,2003,11(1):99-104. 被引量:18
  • 2林祥华,陈志哲,林景娟,吕联煌.人白血病细胞重度联合免疫缺陷小鼠模型的建立和监测[J].福建医科大学学报,2002,36(4):352-355. 被引量:12
  • 3Dick JE,Lapidot T.Biology of normal and acute myeloid leukemia stem cells.Int J Hematol,2005,82:389-396.
  • 4Bonnet D.Normal and leukemic stem cells.Br J Haematol,2005,130:469-479.
  • 5Hope KJ,Jin L,Dick JE.Acute myeloid leukemia originates from a hierarchy of leukemic stem cell slasses that differ in self-renewal capacity.Nat Immunol,2004,5:738-743.
  • 6Goldman J,Gordon M.Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib:does it really matter? Leuk Lymphoma,2006,47:1-7.
  • 7Wang JC,Lapidot T,Cashman JD,et al.High level engraftment of NOD/SCID mice by primitive normal and leukemia hematopoietic cells from patients with chronic myeloid leukemia in chronicphase.Blood,1998,91:2406-2414.
  • 8Ohsugi T,Yamaguchi K,Kumasaka T,et al.Rapid tumor death model for evaluation of new therapeutic agents for adult T cell leukemia.Lab In West,2004,84:263-266.
  • 9Yang YG,Serqio JJ,Pearson DA,et al.Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.Blood,1997,90:4651-4660.
  • 10Steele JP,Clutterbuck RD,Powles RL,et al.Growth of human T cell lineage acute leukemia in severe combined immunodeficiency (SCID)mice and non-obese diabetic SCID mice.Blood,1997,90:2015-2019.

二级参考文献43

  • 1Bobadilla D, Enriquez EL, Alvarez G, et al. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/ EVI1 rearrangements in myeloid malignancies. Br J Haematol, 2007, 136: 806-813.
  • 2Alpar D, Kajtar B, Kneif M, et al. Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet, 2007, 173: 23-30.
  • 3Al-Mawali A, Gillis D, Hissaria P, et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol, 2008, 129: 934-945.
  • 4van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 2003, 17: 1013-1034.
  • 5Elmaagacli AH. Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders. Methods Mol Med, 2007, 134: 161-178.
  • 6Yamada MF, Fujiwara T, Ishikawa I, et al. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan. Tohoku J Exp Med, 2008, 214: 97-104.
  • 7Kim HR, Shin JH, Lee JN, et al. Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia. Korean J Lab Med, 2007, 27: 305-312.
  • 8Hamalainen MM, Kairisto V, Juvonen V, et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol, 2008, 80: 201-207.
  • 9Kerst G, Bergold N, Gieseke F, et al. WT1 protein expression in childhood acute leukemia. Am J Hematol, 2008, 83: 382-386.
  • 10Cloos J, Goemans BF, Hess C J, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 2006, 20: 1217-1220.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部